Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Felix Friedrich

Showing results (11-20 of 12) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 12 results.
The British Journal of Ophthalmology|May 24, 2022
Development of retinal atrophy after subretinal gene therapy with voretigene neparvovecFelix Friedrich Reichel, Immanuel Seitz, Fabian Wozar, et al.
The British Journal of Ophthalmology|May 19, 2021
Three-year results of phase I retinal gene therapy trial for CNGA3-mutated achromatopsia: results of a non randomised controlled trialFelix Friedrich Reichel, Stylianos Michalakis, Barbara Wilhelm, et al.
Pageof 2

Showing results (11-20 of 12) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 12 results.
The British Journal of Ophthalmology|May 24, 2022
Development of retinal atrophy after subretinal gene therapy with voretigene neparvovecFelix Friedrich Reichel, Immanuel Seitz, Fabian Wozar, et al.
The British Journal of Ophthalmology|May 19, 2021
Three-year results of phase I retinal gene therapy trial for CNGA3-mutated achromatopsia: results of a non randomised controlled trialFelix Friedrich Reichel, Stylianos Michalakis, Barbara Wilhelm, et al.
Pageof 2